Troutman Pepper Advises Clinical Dermatology Company Botanix Pharmaceuticals in Acquisition of Sofpironium Bromide

BERWYN, Pa. – Troutman Pepper client Botanix Pharmaceuticals Limited (ASX: BOT), a clinical dermatology company, has announced the acquisition of Sofpironium Bromide gel, 15%, from Brickell Biotech Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company. The gel was developed to treat primary axillary hyperhidrosis, a medical condition that results in excessive underarm sweating. Read a company press release about the acquisition.

The successful acquisition of Sofpironium Bromide advances Botanix toward its goal of becoming a leading commercial dermatology company. More than 15 million patients suffer from hyperhidrosis in the United States alone. Existing therapies are not ideal, either because of the lack of efficacy, unfavorable side effect profile, risk of drug exposure to the skin, or pain from invasive procedures or surgery.

The Troutman Pepper team advising Botanix in the acquisition is led by Timothy Atkins and includes Christopher Bodle, Dawn Hall, James Hipolit, Alicia Palladino, Thomas Phelan, Ryan Salem, Daniel Scolnick, and Michael Walker, among others.

Troutman Pepper has more than 150 attorneys who represent clients such as innovative biotech, pharmaceutical and medical device developers and manufacturers; physicians, hospitals and other health care providers; health insurers and other payors; and a wide range of members of the health care supply chain. The firm has a highly regard life sciences transactional team that handles all types of corporate matters in the space — governance and general corporate advice; M&A transactions; licensing transactions and other complex collaborations; IPOs, follow-on public offerings, PIPE transactions, and other capital markets transactions; seed and later-stage venture capital financings; and much more.

About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm’s litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients’ most pressing business challenges, with depth across industry sectors, including energy, financial services, health sciences, insurance, and private equity, among others. Learn more at troutman.com.